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ensure that it doesn’t mislead 
consumers. When a drug maker 
publishes or broadcasts a claim 
that its drug has benefits in a par-
ticular disease, the FDA requires 
it to include information on the 
product’s risks as well. Since it’s 
not feasible for companies to in-
clude all the important informa-
tion about their products in a 
television ad, the FDA requires 
them to refer viewers to more 
complete information, such as that 
in a printed magazine ad. Com-
panies have tended to comply 
with this requirement by supple-
menting colorful, persuasive ads 
with one or two pages of dry text 
providing the required disclosures, 
often simply using language that 
the FDA has approved for other 
purposes, such as package inserts 
for prescribers. But research shows 
that most patients who attempt to 
read these disclosures find them 
difficult to understand, and many 
don’t even try to make sense of 
them.1 Now, the FDA is in the 
process of adjusting its DTCA 
rules, aiming to provide greater 
assurance that patients receive 
due warning of the most signifi-
cant risks — but its tweaks prob-
ably don’t go far enough to really 
empower consumers to make 
smart decisions about the drugs 
they put into their bodies.
This spring, the FDA revised its 
guidance for communicating risks 
in DTCA, which had been in 
“draft” form since 2004.1 The 
agency has long recommended the 
use of nontechnical language (e.g., 
“drowsiness” rather than “somno-
lence”) but now also recommends 
using an evidence-based format 
for conveying such information. 
The FDA’s research supports the 
use of a “Drug Facts” box, of the 
type that has proven successful 
for over-the-counter products, 
with familiar headings for “Uses” 
and “Warnings.” Alternatively, 
companies will be allowed to use 
a question-and-answer format, as 
some have already been doing.
The draft guidance gives com-
panies additional discretion about 
which risks to disclose and how. 
Though the FDA continues to in-
sist that any “black-box” warnings 
and contraindications be included, 
companies will now be able to 
omit mention of other adverse 
events. The guidance directs com-
panies to include only the “most 
serious and the most common” 
risks posed by a product. The 
idea that it actually helps to give 
consumers less of the available 
information about a product’s 
risks may be counterintuitive, but 
the FDA is reasonably concerned 
that the recital of extremely rare 
risks can distract from, or even 
New DTCA Guidance — Enough to Empower Consumers?
Christopher T. Robertson, J.D., Ph.D.
As one of only two countries that permit direct-to-consumer advertising (DTCA) of pharmaceuti-
cals, the United States tasks the Food and Drug Ad-
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trivialize, the more significant 
disadvantages of a product.
Still, the guidance raises dif-
ficult questions about which risks 
to exclude, and it’s worrisome 
when discretion is given to mar-
keters who have an interest in 
downplaying overall risks. For 
the industry, such discretion is a 
double-edged sword. If a patient 
experiences an adverse effect and 
files a lawsuit, a civil jury may 
find that the advertising was mis-
leading, and a company’s defense 
may receive little support from 
the FDA’s vague guidance. Some 
conservative companies may there-
fore prefer to continue providing 
comprehensive lists, and the new 
guidance allows them to do so. 
If the FDA is serious about 
streamlining disclosures, it may 
need to take a stronger approach.
Moreover, the new guidance is 
not particularly clear or coherent. 
For example, it states that the 
“FDA does not intend to object 
if a firm does not include ‘each 
specific side effect and contra-
indication,’” but a few pages later, 
it says that “information address-
ing the following should be in-
cluded: . . . All Contraindica-
tions.”1 Admittedly, this is only a 
draft document, and clearer guid-
ance may be provided in the final 
version. Unfortunately, the FDA 
often allows draft documents to 
linger for years — the previous 
draft guidelines on print adver-
tisements were still not finalized 
even after a decade. Even final 
guidance documents are techni-
cally not binding, but even in draft 
form they tend to be very influ-
ential in an industry that must 
work with the FDA on a daily ba-
sis. When the guidance remains 
in draft form perpetually, how-
ever, it exacerbates the regulatory 
ambiguity.
But these concerns are super-
ficial in the context of broader, 
more fundamental questions about 
risk disclosure as a regulatory 
mechanism. From the latter per-
spective, the guidance represents 
a relatively modest reform, which 
retains the basic regulatory struc-
ture permitting DTCA but re-
quires accompanying disclosures 
to mitigate potential harms. The 
FDA could instead have issued 
highly restrictive guidelines, per-
haps cracking down on indus-
try’s use of noncognitive persua-
sion (think bathtubs in a field of 
flowers to suggest the romance 
made possible by an erectile-dys-
function drug), which may under-
mine rational decision making by 
patients.2 (Ironically, when the 
FDA tried to use its own emotion-
al appeals in the form of graphic 
cigarette warnings, industry play-
ers objected vociferously.) But the 
Supreme Court’s recent First 
Amendment jurisprudence — 
granting companies rights to free 
speech for commercial activities 
— would probably constrain such 
an aggressive approach. In recent 
years, the FDA has sought to 
avoid litigation for fear that the 
Court might overreact, further 
limiting its regulatory ambit.
The Court tends to favor an 
approach whereby regulators allow 
companies to advertise but re-
quire them to append disclosures 
to add balance and protect con-
sumer welfare. As legal scholars 
Carl Schneider and Omri Ben-
Shahar have argued, however, as a 
regulatory tool, mandatory “dis-
closure is a fundamental failure 
that cannot be fundamentally 
fixed.”3 They cite examples from 
myriad domains in which policy-
makers have reflexively turned to 
disclosure as a regulatory tool — 
and it has failed. Tweaking the 
disclosure regime, as the FDA is 
doing here, has proven ineffec-
tual. The regulators of the mort-
gage industry, in particular, have 
tried to simplify its disclosures 
to home buyers, but they’ve had 
little success in changing the be-
havior of consumers or of the 
brokers who stand between them 
and lenders. Disclosures are no 
substitute for regulation of the 
products themselves to ensure 
that they provide net benefits to 
those who consume them, and 
they are no substitute for having 
well-trained and unconflicted ad-
visors (e.g., prescribers) ensuring 
that the product is a good match 
for the consumer (e.g., the patient).
If disclosure is to work, as 
others have argued, it must be 
done right, in a format that’s de-
signed to be usable. As an exam-
ple of success, Fung et al. cite 
the simple, salient, and familiar 
“A, B, C” system used to rate res-
taurants on the basis of public 
health inspections, with the re-
sults posted prominently by the 
door.4 The new FDA guidance is 
a move in this direction, at least 
if it gives companies more liberty 
to construct readable disclosures. 
However, even revised disclosures 
written by the companies them-
selves are unlikely to be simple 
and candid enough to steer pa-
tients away from drugs that are 
inappropriate for them. One can 
imagine a system that would 
grant drugs an “A” rating if they 
proved a substantial advance over 
the previous standard of care in 
treating a serious medical condi-
tion, with minimal risks or side 
effects. Regrettably, many of the 
most widely advertised drugs 
would not secure that golden ring.
Unfortunately, the FDA’s guid-
ance will do nothing to help con-
sumers understand whether drugs 
really have substantial benefits. 
Research has shown that a more 
expansive Drug Facts box could 
comprehensibly convey data on 
the proportion of patients who 
actually benefited from the drug 
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in key trials and how many had 
adverse events.5 If patients and 
prescribers used such informa-
tion to make intelligent choices 
about one drug versus another — 
or about forgoing medication alto-
gether — it could drive genuine 
competition and innovation in 
the pharmaceutical 
market. That would 
reflect the sort of 
“consumer empowerment” that 
free-speech advocates have used 
to justify DTCA in the first place. 
But such an advance awaits bolder 
action by the FDA and the phar-
maceutical industry.
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The Vernacular of Risk — Rethinking Direct-to-Consumer 
Advertising of Pharmaceuticals
Jeremy A. Greene, M.D., Ph.D., and Elizabeth S. Watkins, Ph.D.
A side from New Zealand, the United States is the only 
country with a strong pharma-
ceutical regulatory infrastructure 
that allows direct-to-consumer 
advertising (DTCA) of prescrip-
tion drugs in print, broadcast, 
and electronic media. U.S. con-
sumers are accustomed to full-
page ads in newspapers and 
magazines detailing a drug’s 
benefits — followed by another 
page of fine print in which its 
contraindications, risks, and side 
effects are spelled out in minute 
detail and equally minute print.
That may soon change, how-
ever, as the Food and Drug Ad-
ministration (FDA) moves to en-
act new regulations regarding risk 
communication in DTCA. Earlier 
this year, the FDA sought public 
comments on new guidance for 
pharmaceutical marketers on com-
municating risks to consumers in 
print advertisements. This pro-
posal, which the FDA has kicked 
around in one form or another 
since 2004, responds to mount-
ing research showing that re-
printing highly technical package 
inserts in print ads does very 
little to communicate risks to 
consumers. The goal is to com-
municate those risks in a new 
vernacular.
Instead of reproducing the fine 
print meant for physicians and 
pharmacists, the FDA proposes 
that drug marketers use a new 
“consumer brief summary” fo-
cused “on the most important 
risk information . . . in a way 
most likely to be understood by 
consumers.” A summary written 
in everyday language might take 
the form of a Q&A list, for ex-
ample, or a Drug Facts box like 
those on packaging for over-the-
counter medicines. Drug market-
ers are being asked to use popu-
lar idiom to communicate with 
people with a wide range of liter-
acy levels; to use larger fonts and 
more readable formats; and to use 
visual elements such as white 
space, logos, and color schemes to 
highlight the most relevant risks.1
Public comments on the pro-
posal have focused on the chal-
lenges of implementation. How 
many risks are too many to 
print? How will a manufacturer 
— or the FDA — know when 
language is too simple, too tech-
nical, or pitched “just right” for 
average Americans? Missing from 
this conversation is a broader 
perspective on the vernacular of 
risk in pharmaceutical promotion 
— as something that is not a 
new DTCA-related duty for the 
FDA but fundamental to the ori-
gins of the category of prescrip-
tion drugs and their regulation 
over the past half-century.
After passage of the 1938 Food, 
Drug, and Cosmetic Act, which 
established the distinction be-
tween prescription-only and over-
the-counter drugs, consumers re-
ceived most information about 
the latter through ads and most 
about the former from their phy-
sician or pharmacist. Indeed, the 
category of “prescription-only” 
medications enabled industry to 
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